I've been manufacturing hemp gummies in Louisville since 2016. Most of that time, CBG was a niche ingredient — interesting chemistry, expensive to source, limited retail shelf space. That is no longer true. In the last 18 months, CBG has moved from specialty supplement shops into mainstream wellness retail, and brands that have built CBG SKUs into their lineups have noted repeat purchase interest in this segment.
This guide explains what CBG is, why it costs more than CBD, how it fits the new H.R. 5371 framework, and where wholesale buyers can position it on the shelf.
On CBG pricing: CBG costs more to source than CBD because it must be harvested before the plant matures — the window when CBGA has not yet converted into other cannabinoids. Yields are lower. That cost gets passed through the supply chain. Any CBG product priced at commodity-CBD levels warrants a close look at the COA.
What Is CBG? The Chemistry Behind the Name
CBG stands for cannabigerol. It is a minor cannabinoid found in hemp, and it plays a foundational role in how the plant produces all other cannabinoids.
The full picture: the hemp plant synthesizes cannabigerolic acid (CBGA) first. CBGA is the precursor. As the plant matures, enzymes convert CBGA into THCA, CBDA, and CBCA — the acidic forms of THC, CBD, and CBC. When the plant reaches full maturity, most CBGA has been converted. Very little is left.
That conversion chain is why CBG is expensive and why it carries the "mother cannabinoid" label in industry marketing. It is not hyperbole — CBGA literally precedes every other cannabinoid on the biosynthesis pathway.
To get meaningful CBG yields, cultivators must harvest early (before full CBGA conversion) or breed strains specifically selected for higher CBG expression at maturity. Both approaches cost more than conventional hemp production. Some producers use extraction and isolation from mature plants, but yields are lower and costs per gram are higher than CBD.
CBG is non-intoxicating. It does not produce psychoactive effects. This is consistent across the research literature and with what we observe in production.
CBG vs. CBD: Different Use Occasions, Different Retail Position
The most common question from wholesale buyers: "I already carry CBD. Why do I need CBG?"
The answer is use occasion and consumer intent.
CBD is the general wellness cannabinoid. Broad demographic. Morning or daytime use is common. It is the baseline product for most hemp and supplement brands — broad in appeal, well understood by consumers.
CBG is positioning toward daytime use occasions. Consumers reaching for CBG are typically looking for something to incorporate into their morning or workday routine — not a sedative, not a sleep aid. The consumer intent is distinctly different from CBD's general wellness framing.
^ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
In retail, this means CBG does not displace your CBD products. It extends your cannabinoid line into a different time-of-day occasion and a different purchase motivation. A retailer with both CBD and CBG SKUs is covering general wellness (CBD) and daytime wellness (CBG) as distinct shelf positions.
The analogies consumers already understand: L-theanine, lion's mane as daytime functional supplements. CBG lands in that same mental space — a naturalistic option for daytime routines, not a stimulant, not a pharmaceutical.
CBG and H.R. 5371 — The Compliance Picture
H.R. 5371 caps total THC in finished hemp products at 0.4 mg per finished container. Not per serving. Not per gummy. Per container. Enforcement begins November 12, 2026.
CBG is not THC. The statute targets THC and its analogs. CBG is a separate cannabinoid on a separate biosynthetic branch.
At normal commercial formulation levels — 5 mg, 10 mg, or 20 mg CBG per gummy — total residual THC in a finished container comes in well under the 0.4 mg cap from a properly sourced, well-manufactured product. We track this on every batch COA.
This matters strategically. Some of the high-volume SKUs currently on the market depend on delta-8 THC or elevated delta-9. Those SKUs face a real shelf-life problem under H.R. 5371. CBG faces no such problem. It is non-intoxicating, it is not a THC analog, and it passes the H.R. 5371 framework cleanly at normal commercial doses.
Wholesale buyers building a product line for 2026 and beyond should be thinking about which cannabinoids survive the regulatory transition. CBG is in a good position.
More on how we approach compliance is at /compliance/. If you want to run your current SKU mix against the H.R. 5371 framework before enforcement begins, HempData offers that analysis.
Wholesale Dosing Ranges for CBG
The CBG dosing range in commercial products has evolved over the last few years. Here is where the market has settled.
5 mg per gummy — The entry point for CBG. Common in combination SKUs (CBG + CBD, or CBG + L-theanine), and increasingly popular as a standalone microdose format. Five-milligram CBG gummies have been showing up in smoke shops and specialty wellness retailers as an accessible trial SKU. The price point is lower, which helps with consumer adoption.
10 mg per gummy — Standard for a dedicated CBG product. This is the dose most supplement buyers gravitate toward when they want a single-cannabinoid CBG SKU with clear positioning. Good for health food stores and natural grocery channels.
20 mg per gummy — Premium positioning. This is where brands with an established CBG customer base tend to take their "professional strength" or "high potency" line extension. Margins are stronger at this level, and consumers who have found a 10 mg dose that works for their routine will often upgrade.
For private-label CBG gummies with your branding, our minimum order quantities and current pricing are on the /wholesale-pricing/ page. We also carry bulk CBG gummies for brands that do their own packaging — details at /bulk-cbg-gummies-wholesale/.
Where CBG Is Moving at Retail
The retail landscape for CBG has changed. Here is what I am seeing across the channels we supply.
Health food and natural grocery: CBG positions well in these channels as a daytime wellness supplement alongside lion's mane, L-theanine, and adaptogenic stacks. The consumer here reads labels and understands supplement language. A clear, honest CBG panel with a clean COA is what converts in this channel.
Smoke shops and hemp specialty retail: Five-milligram CBG gummies are entering smoke shops as affordable minor cannabinoid trial SKUs. The consumer in this channel is already cannabinoid-literate and is looking to try something new without committing to a full-size product at premium pricing. Small-format, lower-dose CBG sells well here.
Online DTC: CBG stacks — CBG paired with L-theanine, or CBG with lion's mane — are performing in direct-to-consumer channels. The consumer is searching for a daytime functional wellness supplement and finding cannabinoids through that query path rather than the traditional CBD search path.
Supplement retailers (national chains): CBG is beginning to appear in the daytime wellness sections of larger supplement retailers. This channel can be slower to adopt new ingredients but has potential for meaningful unit volume once a SKU is authorized.
The trend worth watching: microdose positioning. Five-milligram CBG gummies taken as a daily functional supplement — rather than a therapeutic product — is the framing that seems to resonate with mainstream supplement consumers who might be cautious about higher doses.
Frequently Asked Questions
Why is CBG so much more expensive than CBD?
CBG must be harvested before the plant fully matures, or grown from strains selectively bred for higher CBG expression. At full maturity, most CBGA has already converted to THC, CBD, and CBC — so there is very little CBG left. Lower yield per plant, more specialized cultivation, and additional extraction complexity all push the cost up. Expect to pay a meaningful premium over commodity CBD. Any CBG product priced at CBD levels deserves a hard look at the sourcing and the COA.
Will CBG make you feel high or intoxicated?
No. CBG is non-intoxicating. It does not produce psychoactive effects. This is consistent across what the limited preliminary research shows and with what we see from our own products in the market. If a supplier or brand is claiming otherwise — in either direction — that is a red flag.
Is CBG legal under H.R. 5371?
CBG is a hemp-derived cannabinoid and is not a THC analog. The 0.4 mg total-THC-per-container cap set by H.R. 5371 (enforcement November 12, 2026) does not apply to CBG itself. However, your finished product still needs to meet that total-THC cap — meaning the batch COA for your CBG gummy should confirm total THC is under 0.4 mg per container. Hemp product regulations vary by state; check your specific jurisdiction. We do not make 50-state legality claims.
Does CBG help with focus?
We do not make claims that CBG treats any condition, including attention or cognitive disorders. What we can say: CBG is used by consumers as part of a daytime wellness routine, and the retail category has positioned CBG alongside other non-stimulating daytime supplements. That positioning is based on use occasion and consumer intent, not medical claims. Limited preliminary research exists but does not establish any health outcomes.
^ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Can CBG be private-labeled?
Yes. We offer private-label CBG gummies with full branding, label design support, and compliance documentation. We can also formulate combination SKUs — CBG with CBD, CBG with L-theanine, or other formulations — with sufficient lead time. Minimums and pricing at /wholesale-pricing/. Custom formulation requests should come through the quote form so we can confirm feasibility and lead time before you plan your launch.
How do I evaluate a CBG supplier's COA?
A CBG COA should confirm: (1) CBG potency at or above the labeled dose, (2) total THC — should be well under 0.4 mg per finished container under H.R. 5371, (3) full cannabinoid panel so you know what else is in the product, (4) residual solvents, (5) heavy metals, (6) microbials. The COA should be batch-specific, not a generic product document, and issued by an ISO/IEC 17025-accredited laboratory. CBG potency testing requires equipment calibrated for minor cannabinoid detection — not all labs are set up equally for this. Ask about your supplier's lab relationships.
Sources
- U.S. Congress. H.R. 5371 — Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act. Congress.gov
- Russo, E.B. et al. "Cannabidiol and Other Cannabinoids: Research and Clinical Perspectives." Frontiers in Neuroscience. (Cited for general cannabinoid research context; does not address CBG specifically.)
- Congressional Research Service. "Hemp as an Agricultural Commodity." CRS Report RL32725. CRS.gov
- National Institutes of Health / National Center for Complementary and Integrative Health. "Cannabis (Marijuana) and Cannabinoids: What You Need to Know." NCCIH/NIH
Ready to add CBG gummies to your lineup? Request a wholesale quote and we'll have pricing back to you within one business day.
These statements have not been evaluated by the FDA. Our products are not intended to diagnose, treat, cure, or prevent any disease.